Skip to main content

Table 1 Patient baseline characteristics

From: Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity

Age (years) 57 ± 16
Male, n (%) 8 (27)
BMI (kg/m2) 23.3 ± 4.8
WHO functional classification II/III/IV 5/15/10
Idiopathic/porto/CTD 13/6/11
Laboratory
 BNP (pg/mL) * 391 (69–558)
Swan–Ganz data
 RAP (mm Hg) 6.1 ± 4.2
 Systolic PAP (mm Hg) 73.9 ± 20.2
 Diastolic PAP (mm Hg) 28.9 ± 8.5
 Mean PAP (mm Hg) 46 ± 12
 PAWP (mm Hg) 9 ± 4.3
 CO (L/min) 4.06 ± 1.42
 CI (L/min/m2) 2.68 ± 0.93
 PVR (Wood units) 11.3 ± 6.8
 SvO2 (%) 64.1 ± 8.9
Pulmonary Function Testing
 FEV1% 76.9 ± 11.2
 %VC 87.4 ± 19.8
 %DLCO 61.2 ± 26.4
Cardiopulmonary Exercise Testing
 Peak VO2 (mL/min/kg) 12.1 ± 4.4
 VE/VCO2 slope 55.1 ± 20.3
  1. Data are presented as mean ± SD or median (interquartile range)
  2. BSA Body surface area, BNP Brain natriuretic peptide, CI Cardiac index, CO Cardiac output, CTD Connective tissue disease, DLCO Carbon monoxide lung diffusing capacity, FEV1% Forced expiratory volume, PAP Pulmonary arterial pressure, PAWP Pulmonary artery wedge pressure, Porto Portopulmonary hypertension, PVR Pulmonary vascular resistance, RAP Right atrial pressure, SvO2 mixed venous oxygen saturation, UA Uric acid, VC Vital capacity, WHO World Health Organization
  3. * Normal range for BNP, < 18.4 pg/mL